Showing results 8 to 13 of 13
< previous
Title | Author(s) | Issue Date | |
---|---|---|---|
Reduction of hepatitis B surface antigen mediated by RNA interference therapeutic AB-729 in chronic hepatitis B patients is associated with T cell activation and a decline in exhausted CD8 T cells. Poster Presentation (SAT397) Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology | 2022 | ||
Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression Proceeding/Conference:Journal of Hepatology | 2021 | ||
Safety and pharmacodynamics of the GALNAC-siRNA AB-729 in subjects with chronic hepatitis B infection Proceeding/Conference:Hepatology | 2020 | ||
4-Oct-2022 | |||
Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the 3rd generation capsid inhibitor AB-836 in healthy subjects(HS) and subjects with chronic hepatitis B (CHB). Poster Presentation (SAT392) Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology | 2022 | ||
2019 |